The proportion of clinical trials in phase I has increased significantly over recent years from 25% in 2001 to around 40% today. This coupled with the number of high profile phase III failures has put increased emphasis on making the right decision as early as possible.
Unlocking the potential of imaging, biomarkers and alternative trial designs has the power to greatly reduce the time and cost of your trial and speed time to market. With 16 industry experts, 2 regulators and 7 discussion and networking sessions providing a how to approach to implementing these techniques, Pharma IQ's 2nd Annual Innovation in Phase Clinical Development conference can't be missed!
Exclusive Case Study
One of the latest approaches to reduce attrition rates and save costs is through the magic of Positron Emission Tomography (PET) Imaging! Eugenii (Ilan) A. Rabiner, Head, Clinical Imaging Applications, GSK Clinical Imaging Centre will be providing you with the latest developments in imaging techniques and uses.
Download the brochure here for more information.
New additions to the 2011 programme:
- Streamed sessions to tailor your learning
- More interactive breakout and networking sessions - seize the opportunity to have your say!
- Access to e-networker; set up meetings and interact with your peers prior to the event
- A showcase of imaging techniques to help make go no/go decisions as early as possible
- Back by popular demand! More focus on trial design methodologies to save time and spot problems from the outset
Top 5 Reasons to Attend
- Regulatory insight session; get clarification of their expectations and requirements, as well as an overview of the new ICH S9 guidance!
- Make informed decisions before entering the clinic through effective use of preclinical data and establishing IVIVE
- Ensure patient safety and operational excellence through effective CRO monitoring, maintaining GCP and effective data reporting
- Get the small biotech perspective on CRO selection and relationship management: getting our voices heard
- Successfully implement imaging during early clinical development - weighing the pros and cons
Still not convinced? find out more..